Burkitt's lymphoma
ICD-10 C83.7 · ICD-11 2A85.6

Burkitt's Lymphoma When First-Line Immunochemotherapy Has Not Achieved Complete Remission

In patients with Burkitt's lymphoma whose disease has relapsed or become refractory after initial treatment, the clinical situation calls for a defined next-line approach. This protocol applies when first-line intensive multiagent immunochemotherapy with rituximab has been completed but complete remission — confirmed by a negative PET scan — has not been reached.

Prior Line — Failure Condition

First-line treatment involved intensive multiagent immunochemotherapy with rituximab (regimens such as DA-EPOCH-R or R-CODOX-M/IVAC), including systemic and intrathecal CNS-directed therapy.

Goal not achieved — triggering escalation Achievement of complete remission of lymphoma, confirmed by a negative PET scan.

Next-Line Approach

For relapsed or refractory disease, the approach involves salvage therapy combining rituximab with an infusional second-line chemotherapy regimen, with the aim of bridging to allogeneic stem cell transplant.

Full regimen details, sequencing, and eligibility criteria are in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood.2019004099

Rituximab plus infusional second therapy followed by allogeneic transplant was associated with 67% survival compared with 18% with all other approaches.

View source ↗